Endo International plc (ENDP) Income Statement Analysis

See more : R3D Resources Limited (R3D.AX) Income Statement Analysis – Financial Results

Complete financial analysis of Endo International plc (ENDP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Endo International plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Orient Overseas (International) Limited (OROVY) Income Statement Analysis – Financial Results
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) Income Statement Analysis – Financial Results
Iron Horse Acquisitions Corp. Unit (IROHU) Income Statement Analysis – Financial Results
Team17 Group plc (TM17.L) Income Statement Analysis – Financial Results
GWR Group Limited (GWR.AX) Income Statement Analysis – Financial Results

Endo International plc (ENDP)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.endo.com

About Endo International plc

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Metric	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	2.99B	2.90B	2.91B	2.95B	3.47B	4.01B	3.27B	2.88B	2.62B	3.03B	2.73B	1.72B	1.46B	1.26B	1.09B	909.66M	820.16M	615.10M	595.61M	398.97M	251.98M	197.43M	138.55M	108.37M
Cost of Revenue	1.22B	1.44B	1.57B	1.63B	2.23B	2.63B	2.08B	1.40B	1.04B	1.26B	1.07B	504.76M	375.06M	267.24M	217.37M	201.42M	186.35M	140.99M	135.67M	98.86M	74.89M	61.81M	58.26M	54.73M
Gross Profit	1.77B	1.46B	1.35B	1.32B	1.24B	1.38B	1.19B	1.48B	1.58B	1.77B	1.66B	1.21B	1.09B	993.30M	868.24M	708.24M	633.81M	474.11M	459.94M	300.12M	177.09M	135.62M	80.28M	53.64M
Gross Profit Ratio	59.21%	50.31%	46.15%	44.63%	35.76%	34.29%	36.50%	51.32%	60.28%	58.34%	60.98%	70.59%	74.33%	78.80%	79.98%	77.86%	77.28%	77.08%	77.22%	75.22%	70.28%	68.69%	57.95%	49.50%
Research & Development	148.56M	158.90M	130.73M	185.83M	172.07M	183.37M	102.20M	154.20M	142.47M	226.12M	182.29M	144.53M	185.32M	110.21M	138.26M	82.81M	88.31M	50.55M	51.02M	56.82M	38.99M	26.01M	9.37M	5.89M
General & Administrative	0.00	698.51M	632.42M	646.04M	629.87M	770.73M	741.30M	795.86M	0.00	0.00	0.00	18.98M	93.08M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	861.76M	698.51M	632.42M	646.04M	629.87M	770.73M	741.30M	795.86M	0.00	0.00	0.00	18.98M	93.08M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	849.34M	898.85M	858.17M	547.61M	348.36M	496.15M	412.76M	388.86M	232.26M	194.63M	306.62M	157.71M	165.99M	85.40M	51.23M	32.91M
Operating Expenses	1.01B	857.41M	763.15M	831.86M	801.94M	954.10M	843.50M	950.06M	991.81M	1.12B	1.04B	711.11M	626.76M	606.36M	551.01M	471.66M	320.57M	245.18M	357.65M	214.53M	204.99M	111.41M	60.60M	38.81M
Cost & Expenses	2.23B	2.30B	2.33B	2.46B	3.03B	3.59B	2.92B	2.35B	2.03B	2.39B	2.11B	1.22B	1.00B	873.59M	768.38M	673.08M	506.92M	386.17M	493.32M	313.39M	279.88M	173.21M	118.87M	93.54M
Interest Income	0.00	4.17M	19.95M	13.19M	6.47M	3.72M	5.69M	4.05M	1.33M	406.00K	599.00K	1.36M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	562.35M	537.11M	558.68M	534.85M	494.69M	456.40M	378.90M	231.16M	174.93M	183.24M	148.62M	47.96M	37.72M	8.35M	117.00K	0.00	0.00	0.00	258.00K	4.39M	10.96M	15.12M	0.00	0.00
Depreciation & Amortization	457.10M	518.81M	612.86M	723.71M	983.77M	983.31M	632.76M	331.65M	255.66M	285.52M	237.41M	108.40M	99.88M	49.91M	16.29M	17.85M	15.88M	11.02M	6.67M	3.53M	58.29M	28.86M	8.31M	7.37M
EBITDA	472.85M	472.97M	764.59M	250.02M	-807.27M	-2.61B	-300.40M	-560.34M	-278.82M	-325.14M	683.28M	549.04M	497.26M	460.46M	369.66M	251.58M	340.12M	242.12M	115.93M	68.82M	28.95M	-119.04M	13.64M	7.57M
EBITDA Ratio	15.80%	33.27%	26.24%	8.48%	-23.27%	-65.02%	-49.59%	-19.48%	-10.65%	-10.74%	25.03%	31.99%	34.04%	36.53%	34.05%	27.66%	41.47%	39.36%	19.46%	17.25%	11.49%	-60.30%	9.85%	6.99%
Operating Income	15.75M	603.16M	581.87M	-469.13M	-960.07M	-3.47B	-933.48M	-896.94M	-425.63M	-551.73M	508.37M	465.37M	390.02M	387.47M	317.23M	210.53M	313.25M	228.94M	109.26M	65.29M	-27.90M	24.22M	19.68M	14.83M
Operating Income Ratio	0.53%	20.78%	19.97%	-15.92%	-27.68%	-86.57%	-28.56%	-31.17%	-16.26%	-18.22%	18.62%	27.12%	26.70%	30.74%	29.22%	23.14%	38.19%	37.22%	18.34%	16.36%	-11.07%	12.27%	14.20%	13.69%
Total Other Income/Expenses	-562.35M	-629.67M	-926.78M	-469.70M	-522.94M	-452.34M	-1.14B	-228.76M	-133.94M	-189.86M	-156.68M	-44.67M	-30.36M	14.73M	36.02M	23.21M	11.00M	2.16M	-258.00K	-4.39M	-10.96M	-187.24M	-14.35M	-14.45M
Income Before Tax	-546.60M	-26.52M	-344.90M	-938.83M	-1.48B	-3.92B	-1.44B	-1.13B	-559.57M	-741.58M	351.69M	420.70M	359.66M	402.20M	353.25M	233.73M	324.24M	231.10M	109.00M	60.89M	-38.86M	-163.02M	5.33M	382.00K
Income Before Tax Ratio	-18.26%	-0.91%	-11.83%	-31.86%	-42.75%	-97.85%	-43.99%	-39.13%	-21.38%	-24.50%	12.88%	24.51%	24.62%	31.91%	32.54%	25.69%	39.53%	37.57%	18.30%	15.26%	-15.42%	-82.57%	3.85%	0.35%
Income Tax Expense	22.48M	-273.98M	15.68M	22.94M	-250.29M	-700.08M	-1.14B	-401.84M	-24.07M	-53.56M	109.63M	133.68M	93.32M	140.46M	125.81M	95.90M	121.95M	87.79M	39.21M	30.08M	-3.75M	-6.18M	2.07M	-14.45M
Net Income	-569.08M	183.94M	-422.64M	-1.03B	-2.04B	-3.35B	-1.50B	-721.32M	-685.34M	-740.34M	187.61M	259.01M	266.34M	261.74M	227.44M	137.84M	202.30M	143.31M	69.79M	30.81M	-36.54M	-156.84M	3.26M	201.00K
Net Income Ratio	-19.01%	6.34%	-14.50%	-35.00%	-58.68%	-83.46%	-45.74%	-25.07%	-26.19%	-24.45%	6.87%	15.09%	18.23%	20.76%	20.95%	15.15%	24.67%	23.30%	11.72%	7.72%	-14.50%	-79.44%	2.35%	0.19%
EPS	-2.44	0.79	-1.87	-4.61	-9.12	-15.03	-6.73	-4.69	-5.94	-6.68	1.60	2.23	2.28	2.12	1.70	1.03	1.53	1.09	0.54	0.30	-0.40	-1.97	0.05	0.00
EPS Diluted	-2.44	0.79	-1.87	-4.61	-9.12	-15.03	-6.73	-4.69	-5.94	-6.40	1.55	2.20	2.27	2.12	1.69	1.03	1.52	1.08	0.53	0.30	-0.40	-1.97	0.05	0.00
Weighted Avg Shares Out	232.79M	233.65M	226.05M	223.96M	223.20M	222.65M	222.12M	153.91M	115.35M	110.79M	117.16M	116.06M	117.06M	123.25M	133.90M	133.18M	132.24M	131.81M	128.42M	102.06M	91.51M	79.45M	71.33M	71.31M
Weighted Avg Shares Out (Dil)	232.79M	233.65M	226.05M	223.96M	223.20M	222.65M	222.12M	153.91M	115.35M	115.72M	121.18M	117.95M	117.52M	123.72M	134.53M	133.91M	133.29M	132.72M	132.44M	102.13M	91.51M	79.45M	71.33M	71.31M

Do These Penny Stocks Deserve a Place On Your Watchlist?

September 22, 2021pennystocks.com

Why investors are watching these penny stocks right now The post Do These Penny Stocks Deserve a Place On Your Watchlist? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States

September 22, 2021prnewswire.com

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the generic version of Pfizer's Chantix® (varenicline), 0.5 mg and 1 mg tablets, following final...

Endo (ENDP) Gains on Settlement of Opioid Cases in New York for $50M

September 13, 2021zacks.com

Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.

Why Shares Of Endo International Surged On Friday

September 10, 2021benzinga.com

Endo International (NASDAQ: ENDP) shares are trading higher going into the close after the company announced it settled New York state opioid cases and provided an update on remaining opioid litigation. The company late Thrusday announced it has settled three consolidated...

Biggest Gaining Penny Stocks to Buy? 4 to Watch Right Now

September 10, 2021pennystocks.com

Looking for big gaining penny stocks to watch? Here's 4 that gapped up today The post Biggest Gaining Penny Stocks to Buy?

Endo International stock shoots up 50% as it settles opioid claims

September 10, 2021invezz.com

Endo International plc (NASDAQ: ENDP) climbed more than 50% this morning after it said late on Thursday it will pay $50 million to settle opioid claims by the New York state and its Suffolk and Nassau counties. “I'm happy our...

Endo Shares Move Higher On Settlement Of New York State Opioid Cases

September 10, 2021benzinga.com

Endo International plc (NASDAQ: ENDP) has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids. Endo said the settlement includes no admission of wrongdoing by Endo...

Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation

September 9, 2021prnewswire.com

DUBLIN, Sept. 9, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc., have settled three consolidated cases pending in Suffolk...

Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation

August 31, 2021prnewswire.com

DUBLIN, Aug. 31, 2021 /PRNewswire/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today commented on the United States District Court for the District of Delaware's non-infringement ruling in favor of Eagle Pharmaceuticals Inc. ("Eagle") in patent litigation regarding Eagle's abbreviated new...